A privately held pharmaceutical company based in South San Francisco.

Following a completion of the deal, KAI will become a owned subsidiary of Amgen wholly.P. Morgan Securities LLC acted as exclusive financial advisor and Latham & Watkins acted as legal advisor to KAI on the transaction. Amgen was advised by Sullivan & Cromwell LLP. Related StoriesVUMC, UCSF investigators awarded $6 million NIH grant to build up implantable artificial kidneyPatients with kidney failing at increased threat of developing different types of cancerUT Southwestern evaluates allopurinol drug to avoid nephropathy in Type I diabetes patientsKAI-4169 is an innovative experimental therapy that’s administered intravenously simultaneously the patient is undergoing dialysis.Related StoriesAnxiety connected with poor asthma outcomesSecondhand smoke cigarettes exposure doubles threat of hospitalization for children with asthmaFour types of gut bacterias can protect infants from asthmaTo make their discovery, experts at the MUHC taken out T lymphocytes from asthmatic rats, produced them fluorescent with the addition of a jellyfish gene, and transplanted them into non-asthmatic rats. The fluorescence allowed us to monitor the motion of the T lymphocytes and determine their influence on the non-asthmatic rats, says Dr. Experts were surprised to learn that the T lymphocytes transferred straight to–and infiltrated–the airway wall space of the non-asthmatic rats, causing extensive remodeling.